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ABSTRACT
Objective: To investigate whether patients with rheumatoid arthritis (RA) enrolled in
randomized controlled trials (RCTs) and observational studies may differ in terms of
characteristics that could modify treatment effects, leading to an efficacy-effectiveness
gap.
Methods: We conducted systematic literature reviews to identify RCTs and
observational studies with RA, treated with rituximab, tocilizumab or etanercept. We
extracted baseline characteristics and compared the data of RCTs and observational
studies using fixed-effects meta-analyses for the RCTs and random-effects meta-
analyses for the observational studies. We also assessed whether the baseline
characteristics changed over time.
Results: Compared to patients enrolled in RCTs, those from observational studies
were on average 3.0 years older (p<0.001), suffered from RA for 3.1 years longer
(p<0.001), had 1.6 more prior disease modifying drugs (p=0.00t), and had a lower
Disease Activity Score 28 (DAS 28) (difference -0.6, p<0.001). C-reactive protein and
erythrocyte sedimentation rate levels were slightly higher in RCTs. The Health
Assessment Questionnaire-Disability lndex (HAO-D|) score was slightly lower in the
RCT group. No differences were found in the percentages of included females or
rheumatoid factor positivity. Over time, we found a significant decrease of -0.08 in
DAS-28 and a decrease of -0.04 in HAQ-DI both in patients in RCTs and in patients
from registries. Furthermore, ESR and CRP declined over time in RCT patients, but
not in patients participating in observational studies.
Conclusion: There are substantial systematic differences in patient characteristics
between randomized controlled trials and registries in RA. The efficacy seen in RCTs
may not reflect real-world effectiveness.
Key messages
- There is no systematic review of the efficacy-effectiveness gap in rheumatoid
arthritis.
- There are important differences in rheumatoid arthritis patients regarding the
efficacy-effectiveness gap.
- Randomized controlled trials enrolled patients with better prognostic factors,
potentially overestimating the treatment effect.
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INTRODUCTION
The randomized controlled trial (RCT) is the gold standard for assessing the efficacy
of pharmacologic treatments and other interventions (1). The main advantage of
random treatment allocation is the high internal validity of estimates of treatment
effects. Estimates from RCTs may, however, lack external validity (2) due to their
highly standardized design, strict inclusion and exclusion criteria and fixed treatment
regimens that may often be at odds with realworld conditions (3,4).
ln health technology assessment it is essential to gauge the effectiveness of drugs in
the realworld settings where they will be used (5). Several authors have recommended
using non-randomized studies, clinical databases and registry data (i.e., observational
studies) to assess whether RCT-based estimates apply to a target population (5-8).
Patient characteristics may differ between RCTs and observational studies, and may
modify treatment effects (7) A treatment may be less effective or more effective
depending on age, stage of disease, or comorbidities (8-11). For example, studies
comparing treatment effects between RCTs and observational studies in
cardiovascular disease showed that patients with acute coronary syndrome included
in clinicaltrials were younger, more likely to be men, and had fewer co-morbidities and
risk factors when compared to registry patients (12,13). Similar results were found by
Ezekowitz and colleagues, who compared characteristics of patients with heart failure
between RCTs and observational studies (14). ln this context Eichler and colleagues
(8) coined the term efficacy-effectiveness gap to describe the gap between treatment
effects observed in RCTs and those observed in real world settings.
A comparison of baseline characteristics of patients with rheumatoid arthritis (RA) in
RCTs and observational studies is lacking. We performed a systematic review
extracting baseline characteristics from available RCTs and observational studies in
RA. This review was a deliverable of Workpackage 4 of the GetReal project
(incorporating real-life data into drug development), a consortium of academia,
pharmaceutical companies, health technology assessment agencies, regulators and
patient organizations (15). Using case studies, WP4 developed best practices in
evidence synthesis and predictive modelling, with the goal of improving estimates of
the real world effectiveness of drugs by incorporating the results of RCTs with other
sources of clinical data, including observational data. WP4 obtained access to
individual participant data from clinical trials of three widely used biologics, namely
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etanercept (ETN), rituximab (RTX) and tocilizumab (TCZ), as well as patient registries
in RA. Our systematic review thus also focused on ETN, RTX and fCZ.
METHODS
Search strategy
We performed two systematic reviews; one literature search was done for
observational studies, the other for RCTs. We applied study design search filters from
the BMJ Evidence Centre lnformation Specialists to the Embase and Medline
databases using Ovid (16). We performed the search for observational studies on
March 4, 2015, and the search for RCTs on April 24, 2015. The detailed search
strategies can be found in Supplementary Tables 51-S4, available at Rheumatotogy
online. ln addition, we manually searched known registries and screened reference
lists of all papers
lnclusion criteria and study selection
We included studies of adult patients diagnosed with RA who were treated with RTX,
TCZ or ETN. Studies were required to have reported the following outcomes: Disease
Activity Score 28 (DAS-28), including C-reactive protein (DAS-28-CRP) or erythrocyte
sedimentation rate (DAS-28-ESR), or Health Assessment Questionnaire-Disability
lndex (HAO-D|) scores. The studies had to include at least 30 patients per study arm.
The retrieved titles and abstracts of the identified articles were imported into
EppiReviewer 4 (17). Duplicates across databases were removed, and for each
treatment, the latest publication fulfilling the inclusion criteria was used. Each paper
was independently assessed by two reviewers (G K. and N.H. or G.K. and E.D.), based
on title and abstract and, if the study was potentially eligible, on the full text of the
article. Disagreements were resolved by consensus, after discussion with M.E. or S.R.
whenever necessary.
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Data extraction
Data from each included paper were extracted using a standardized form developed
for this project. Extracted data covered three areas; first, general data included author,
publication year, study design, country, overall number of patients in the study, follow-
up time and the main objective of the study; second, treatment data included drug,
dose, frequency and route of administration; and third, data on patient characteristics
at baseline included number of patients receiving each drug, age, gender, current
smoking, disease duration, comorbidities, ESR, CRP, seropositivity for rheumatoid
factor (RF) or anti-citrullinated protein antibody (ACPA), DAS-28 and HAQ-DI,
switching from another biologic agent to the current drug, number of prior disease-
modifying anti-rheumatic drugs (DMARDs), and use of corticosteroids and other drugs.
We extracted dichotomous data as numbers and percentages. For continuous data,
we extracted the mean or median, together with the standard deviation or range
(minimum/maximum or interquartile range).
Statistical Analysis
We converted medians and ranges to means with standard deviations using the
methods described by Wan et al. (18). For binary data we used the variance estimator
(v) for proportions (p) to derive the standard error: v= p (1 - p). We performed meta-
analyses of patient characteristics separately for RCTs and observational studies,
overall and by drug. lf necessary, we first combined the data from the study arm into a
single mean or proportion using fixed-effect meta-analyses. Secondly, we combined
the data separately for RCTs and observational studies using random-effects meta-
analyses with Knapp-Hartung adjustment (19). We used mixed-effects meta-
regression analyses to assess the differences in patient characteristics between RCTs
and observational studies by including the study design as a dichotomous covariate.
We used restricted maximum-likelihood estimation to assess between-study variance
(tau-squared) and applied the Knapp-Hartung adjustment. We stratified our main
analysis by study type to explore whether the approaches differed in terms of baseline
characteristics. ln further meta-regression analyses, we included the year of
publication of the studies to examine whether patient characteristics of patients
included in RCTs or observational studies changed over calendar time. ln a sensitivity
l
analysis, we excluded phase lV and pragmatic trials, as reported by the trialists. All
analyses were done with the R package metaphor (20).
RESULTS
We identified 308 references in our literature search for RCTs and Sg4 for
observational studies, and considered 89 RCTs and 194 observational studies to be
potentially eligible (supplementary Figure s1 and s2). Fifty-one RCTs and 76
observationalstudies met our inclusion criteria and were included in the meta-analysis.
Study characteristics
The eligible studies were published between 1999 and 2ll|for RCTs and between
2003 and 2015 for observational studies. Among RCTs, we included 5 phase ll
studies, 23 Phase lll studies, 10 Phase lV studies and one pragmatic trial. For the
remaining 12 RCTs we could not retrieve any information on the phase. Observational
studies comprised 17 cohorl, 28 registry and to 31 case series studies. Most
observational studies (71; 93.4o/o) were conducted in a single country whereas almost
half of RCTs (25; 49.0%o) were multi-country trials, mostly involving European
countries. The number of study participants ranged from 70 to 1262 patients for RCTs
and from 30 to 8908 for observational studies. Among RCTs, we include d 17 TCZ, 10
RTX, and 24 ETN trials, and among observational studies, we included 16 TCZ,2g
RTX 28 and 32 ETN studies. Tables 1 and 2 summarize characteristics of RCTs and
observational stud ies.
Co mpariso n of patient ch a racter.sfics
Compared to patients participating in RCTs, those from observational studies were on
average 3.0 years older (p<0.001), suffered from RA for 3.1 years longer (p<0.001)
and had 1.6 more prior DMARDs (p=9.001, Figure 1). Patients in RCTs had higher
disease activity: the DAS-28 was 0.6 points higher in RCT than in observational studies
(p<0.001, Figure 2). CRP and ESR levels were also slightly higher in RCTs, but
differences failed to reach conventional levels of statistical significance (Figure 2).
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Figure 1. Comparison between randomized controlled trials and observational
studies for age, gender, disease duration, and number of prior DMARDs
Similarly, there was little evidence for any difference between HAQ-DI scores,
rheumatoid factor positivity or the proportion of women participating in the studies.
Analyses stratified by drug showed that differences generally were in the same
direction for the three drugs, but tended to be more pronouncedforTCZ and RTX than
for ETN (Figures 1 and 2). Patients on TCZ were 3.9 years older in observational
studies than in RCTs (p<0.001), their disease duration was 2.4years longer (p=0.06),
they had been exposed on average to 1.4 additional DMARDs (p=0.346) and the DAS-
28 was 1.2lower than in RCTs (p<0.001). Similarly, patients on RTX were 3.3 years
older (p=0.0t 3), their disease duration was 2.6 years longer (p=0.05), they had been
exposed to 1.8 more DMARDS (p=0.083) and the DAS-28 was 1.1 point (p<0.001)
lower in observatioÄal studies than in RCTs. Patients on ETN were 2.4 years older in
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observational studies than in RCTs (p=0.017), their disease duration was 3.4 years
longer (p<0.001) , and they had been exposed to 1.6 more DMARDs (p=0.056).
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Figure 2. Comparison between randomized controlled trials and observational
studies for DAS28, HAQ disability index, cRp, ESR, and RF positivity
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There was no difference in DAS28 (0 points, p=0.86). Analyses stratified by study type
gave similar results compared to the main analyses (Supplementary Figure 53 - S11,
available at Rheumatology online, forest plots for all baseline characteristics).
Trends over calendar time
We found that DAS-28 declined over calendar time both in RCTs (slope of -0.08,
p=0.026) and in observational studies (slope of -0.08, p=0.002) (Figure 3).
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HAQ-DI declined slightly over calendar time both in RCTs (slope of -0.04, p=0.004)
and in observational studies (slope of -0.04, p=0.063) (Figure 4).
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Furthermore, ESR and CRP declined over calendar time in RCTs (slope of -1.69,
p=0.009 for ESR and slope of -1.68, p=0.001 for CRP), but not significantly so in
observational studies (Figure 5). There was little evidence for changes in baseline
patient characteristics over time for any of the other socio-demographic or clinical
characteristics (Supp lementary Fig u res S 1 2-S 1 7, av ailable at Rh eu m atology on I i ne).
Sensitivity analysis
In a sensitivity analysis we excluded 10 Phase lV trials and one pragmatic trial. Ten of
the excluded trials included patients on ETN, while one trial included patients onTCZ.
There was no substantial change compared to the main analyses, except that ESR
increased from 46.3 to 49.4 mm/h in RCTs, which is significantly higher than in
observational studies (p=0. 004).
Dtscussrott
ln this study of the characteristics of patients with RA we found clinical relevant
differences between RCTs and observational studies in RA. Compared to RCTs, RA
patients in observational studies were older, disease duration was longer, a higher
number of different DMARDS were administered before starting biologic treatment, and
disease activity was lower at baseline. Over time, baseline DAS28 and HAQ-DI
declined in patients included in RCTs but not in patients from observational databases.
Differences between real-world and trial data are important, especially when making
decisions in everyday clinical practice. Eichler and colteagues argue that the efficacy-
effectiveness gap is due to variability in drug response (8,148) caused by biological
and behavioral factors. Biological factors can be separated into genetic and non-
genetic factors, which in turn qan be further divided into intrinsic and extrinsic factors.
lntrinsic factors are characteristics of the person such as age, sex, body weight,
comorbidities and baseline severity of disease, whereas extrinsic factors relate to
lifestyle factors such'as smoking (8).
Kirsch and colleagues studied all available data of clinical trials submitted to the FDA
for the licensing of four new-generation antidepressants. They found a relationship
between initial disease severity and antidepressant efficacy, an association that was
due to decreased responsiveness to placebo among very severely depressed patients
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as opposed to increased responsiveness to medication (9). Similarly, in patients with
RA a high DAS-28 score at baseline is a good predictor of a decline in the DAS-28
föllowing treatmentwith ETN (149) andTCZ(120). Our review showed higher DAS-28
scores in patients enrolled in RCTs and we can therefore speculate that the response
was better in trial patients than in observational studies. ln other words, the treatment
effect in everyday clinical praxis might be smaller than that in RCTs.
High numbers of prior DMARDs and higher age were associated with decreased
response rates in patients with ETN (148). Older age was also associated with
decreased response rate in age with TCZ (150); these two baseline characteristics
differed significantly between RCTs and observational studies in our analysis.
Predictive factors for better response to biologics were male gender (in ETN treated
patients (148)), non-smokers (ETN (148)), RF positivity (RTXand TC (151)) and tow
HAQ-DI (TCZ (120) and RTX (148)). For all these factors, if data were available, we
found no difference between RCTs and observational studies.
ln ourtime trend analysis, we saw a decrease in baseline DAS-28 and HAQ-DI in RCTs
over the last 10 years. A decrease in DAS-28 has also been shown for other biologics
such as infliximab (152). These findings support the results of an inception cohort study
published 10 years ago, where the trend was thought to be caused by a more
aggressive treatment strategy (1 53).
ln a sensitivity analysis we excluded ten Phase lV clinicaltrials and one pragmatic trial.
lnterestingly, we found no difference compared to the main results described above.
ln particular, the results in the ETN group where ten trials were excluded remained
virtually the same. This may call into question the notion that Phase lV trials accurately
represent real-world scenarios, and that their estimates of comparative effectiveness
are closer to those of observational studies. We acknowledge that the number of
Phase lV and pragmatic trials was small and that the results from our sensitivity
analysis should be interpreted with caution.
Our review has several strengths and weaknesses. Strengths are that the review was
based on a systematic literature search and study selection and screening were
performed independently by two authors. Data extraction was performed by one
person and checked by a second. Our search was comprehensive, but we included
only English-language studies. Also, we did not look into reports by the European
Medicines Agency (EMA) or Food and Drug Administration (FDA). Data for each
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biologic may have been assessed at different time points in each registry. For instance,
in the Rabbit registry, we used data for ETN from 2006, whereas data for RTX was
assessed from a publication in 2013. We cannot exclude the possibility that some of
the included patients were counted twice, because patients might have switched their
treatment from ETN to RTX. However, in the absence of individual patient data we can
only speculate the percentage of patients who switched treatment regimens. Overall,
7 of the 28 included registries had more than one publication, and it is therefore
possible that patients were counted twice.
Since we did not assess outcomes, we did not apply any risk of bias tool or similar
instrument to examine the quality of studies. Our main interest was the characteristics
of patients included in RCTs and observational studies and it is therefore unlikely that
the comparison was distorted by publication or other selection bias.
We transformed median values into mean values. This might lead to bias in the
aggregated mean if the data summarized by the median was clearly not normally
distributed. Since we transformed only about 8% of the values provided in the RCTs
and only about 17% of the values from the observational studies, any bias introduced
is likely small. Several relevant variables were poorly reported: concomitant MTX use,
concomitant DMARD use, percentage of smokers (reported in only one RCT),
comorbidities and ACPA positivity. These variables were therefore not included in our
analyses, despite their potential relevance in the context of generalizing results from
RCTs to realworld settings.
Clearly, more work is required on how best to narrow the efficacy-effectiveness gap.
ln Phase lV and pragmatic trials, inclusion and exclusion criteria need to be widened
to reflect the realworld. The baseline characteristics of patients included in these trials
should better reflect what we found in observational studies. In addition, evidence
synthesis and modeling approaches should be used to combine data from both RCT
and observational studies to generate real-world evidence (15).
ln summary, we found important differences between RA patients included in RCTs as
compared to observational studies; in particular, patients with better prognostic factors
were included in the RCTs, leading to potential overestimation of the treatment effect.
More research is needed to overcome this efficacy-effectiveness gap in RA to generate
real-world evidence.
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